Last reviewed · How we verify

Valchlor (MECHLORETHAMINE)

Recordati · FDA-approved approved Small molecule Verified Quality 70/100

Valchlor (generic name: MECHLORETHAMINE) is a Alkylating Drug [EPC] Small molecule drug developed by Recordati. It is currently FDA-approved (first approved 1949) for Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma. Also known as: chlormethine.

Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death.

Valchlor (Mechlorethamine) is a small molecule alkylating drug originally developed by Recordati Rare and currently owned by the same company. It was first approved by the FDA in 1949 for various cancer indications, including chronic lymphoid leukemia, Hodgkin's disease, and mycosis fungoides. As an off-patent medication, Valchlor is no longer protected by active patents, allowing for potential generic competition. Despite its age, Valchlor remains a commercial product, and its exact mechanism of action is not well understood. Key safety considerations include its potential for severe side effects and the need for careful dosing.

At a glance

Generic nameMECHLORETHAMINE
Also known aschlormethine
SponsorRecordati
Drug classAlkylating Drug [EPC]
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved
First approval1949

Mechanism of action

Mechlorethamine, also known as nitrogen mustard, is an alkylating agent which inhibits rapidly proliferating cells.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Valchlor

What is Valchlor?

Valchlor (MECHLORETHAMINE) is a Alkylating Drug [EPC] drug developed by Recordati, indicated for Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma.

How does Valchlor work?

Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death.

What is Valchlor used for?

Valchlor is indicated for Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma.

Who makes Valchlor?

Valchlor is developed and marketed by Recordati (see full Recordati pipeline at /company/recordati).

What is the generic name of Valchlor?

MECHLORETHAMINE is the generic (nonproprietary) name of Valchlor.

Is Valchlor also known as anything else?

Valchlor is also known as chlormethine.

What drug class is Valchlor in?

Valchlor belongs to the Alkylating Drug [EPC] class. See all Alkylating Drug [EPC] drugs at /class/alkylating-drug-epc.

When was Valchlor approved?

Valchlor was first approved on 1949.

What development phase is Valchlor in?

Valchlor is FDA-approved (marketed).

What are the side effects of Valchlor?

Common side effects of Valchlor include Dermatitis, Pruritus, Bacterial skin infection, Skin ulceration or blistering, Skin hyperpigmentation, Reductions in hemoglobin.

Related